# Preterm Labor Antenatal Treatment

Select antenatal interventions by likelihood and timing of birth, gestational age, membrane status, infection or delivery indications, and neonatal-intent plan. Use a limited tocolytic bridge for steroids or transfer, magnesium sulfate for neuroprotection rather than tocolysis, and prompt delivery when maternal or fetal risks outweigh latency.

**Clinical question:** How should clinicians select antenatal corticosteroids, magnesium sulfate, tocolysis, antibiotics, and transfer for suspected or established preterm labor?

Updated: 2026-09-15T21:40:19.338421+00:00

## What matters in practice
- Use transvaginal cervical length or fetal fibronectin in symptomatic patients with intact membranes when the result will determine admission, transfer, corticosteroids, or tocolysis; cervical length less than 15 mm and fetal fibronectin 50 ng/mL or greater support management as preterm labor. [7][8]
- Give a standard antenatal corticosteroid course when preterm birth is sufficiently likely: betamethasone 12 mg IM every 24 hours for 2 doses or dexamethasone 6 mg IM every 12 hours for 4 doses. [11]
- Use magnesium sulfate for fetal neuroprotection when early preterm birth is imminent, not as a routine tocolytic; monitor urine output, reflexes, cardiopulmonary status, and renal function. [9][11][14]
- Use acute tocolysis only as a short bridge, generally up to 48 hours, to complete corticosteroids or arrange maternal transfer; do not use it when infection, major bleeding with instability, nonreassuring fetal status, fetal demise, or a maternal/fetal indication for delivery is present. [5][14]
- Do not give antibiotics solely to prolong gestation in preterm labor with intact membranes; administer intrapartum group B streptococcal prophylaxis when delivery is imminent. [5]

## Establish whether a 48-hour bridge is appropriate

Treatment selection begins with whether delaying birth is beneficial and safe.

At presentation, determine membrane status, gestational age, cervical change, maternal bleeding or infection, fetal status, and whether neonatal resuscitation is planned. The immediate treatment goal is not suppression of contractions alone; it is either safe time for corticosteroid exposure and maternal transfer or delivery for a contraindication to expectant management. [2][3][5][14]

Do not initiate tocolysis when delivery is indicated or unsafe to defer: intrauterine fetal demise, lethal fetal anomaly, nonreassuring fetal status, severe preeclampsia or eclampsia, chorioamnionitis, or maternal bleeding with hemodynamic instability. Gestational age above 34 weeks is also a contraindication to tocolysis. [14]

With preterm prelabor rupture of membranes, do not treat contractions reflexively. Tocolysis is generally contraindicated, except when there is no evidence of maternal infection and a brief delay is needed for corticosteroid administration, maternal transfer, or both. [14]
- If delivery appears imminent, prioritize the interventions that retain benefit despite limited time: corticosteroids when indicated, magnesium sulfate for neuroprotection when early preterm birth is anticipated, and intrapartum GBS prophylaxis. [1][5][11]
- If a viable or periviable delivery is anticipated, involve the neonatal team before irreversible obstetric decisions; antenatal corticosteroids, magnesium sulfate, delivery planning, and transfer should align with the agreed neonatal-intent plan. [2][3]

*Treatment goal by clinical branch. [5][14]*

| Clinical branch | Immediate action | What not to use as a default |
| --- | --- | --- |
| Established or highly likely preterm birth without a delivery indication | Administer indicated fetal therapies; consider short-course tocolysis only to complete steroid exposure or transfer. [5][11][14] | Maintenance or repeated acute tocolysis. [5] |
| Chorioamnionitis, unstable bleeding, nonreassuring fetal status, severe preeclampsia/eclampsia, demise, or lethal anomaly | Proceed with management directed by the delivery indication; do not delay delivery for tocolysis. [14] | Tocolysis. [14] |
| PPROM without infection when transfer or steroid completion is needed | Consider a limited exception for tocolysis if maternal and fetal status permit. [14] | Routine pregnancy-prolonging tocolysis. [14] |

## Use cervical length or fetal fibronectin when the result changes treatment

Testing is most useful in symptomatic patients with intact membranes and uncertain near-term delivery risk.

For threatened preterm labor with intact membranes, use transvaginal cervical length when available. A cervical length below 15 mm is used to diagnose preterm labor in this pathway; manage a patient with this result as having diagnosed preterm labor when gestational age and clinical circumstances support intervention. [7]

If transvaginal cervical length is unavailable or unacceptable, use fetal fibronectin. A fetal fibronectin concentration of 50 ng/mL or greater is the cited threshold supporting diagnosis of preterm labor; a negative result with resolved symptoms supports discharge with routine follow-up and return precautions rather than automatic admission and antenatal treatment. [7][8]

At 30 weeks or more, NICE identifies fetal fibronectin as a tool to assess likelihood of birth within 48 hours when cervical-length assessment is indicated but unavailable or unacceptable. A positive diagnostic result should move management toward treatment as preterm labor rather than prolonged observation without a delivery-risk plan. [8]
- Order a test only if the result will alter admission, corticosteroid administration, magnesium sulfate planning, transfer, or tocolysis. [7][8]
- Do not apply this intact-membranes testing pathway to PPROM; membrane status changes both diagnostic interpretation and treatment selection. [7][14]

*Actionable testing thresholds in symptomatic threatened preterm labor with intact membranes. [7][8]*

| Test | Actionable result | Management implication |
| --- | --- | --- |
| Transvaginal cervical length | Less than 15 mm. [7] | Treat as diagnosed preterm labor when clinically appropriate. [7] |
| Fetal fibronectin | 50 ng/mL or greater. [7][8] | Supports management as diagnosed preterm labor. [8] |
| Fetal fibronectin with settled symptoms | Negative diagnostic result. [7] | Discharge with routine follow-up and advice to return if symptoms recur or worsen. [7] |

## Give corticosteroids when preterm birth is likely enough to justify exposure

Antenatal corticosteroids are selected for anticipated preterm birth, not for contractions alone.

For a patient at meaningful risk of preterm birth, administer one standard corticosteroid regimen: betamethasone 12 mg intramuscularly every 24 hours for 2 doses, or dexamethasone 6 mg intramuscularly every 12 hours for 4 doses. [11]

Guidelines consistently support antenatal corticosteroids for PPROM between 24 and 34 weeks' gestation, and corticosteroids reduce neonatal morbidity and mortality after PPROM without increasing maternal or neonatal infection in the cited review. [4][20] Do not withhold indicated corticosteroids solely because membranes are ruptured; instead, separately assess for intra-amniotic infection or another reason delivery should not be delayed. [14][20]

A single repeat course may be considered when a prior course was administered at least 7 to 14 days earlier and the patient is again at current risk of preterm birth. The cited source describes either a standard repeat 48-hour regimen or a single betamethasone dose as a rescue approach. [11] Repeat-course decisions require renewed assessment that delivery risk is sufficiently near term, because uncertainty persists across guidelines regarding repeat courses and use outside the conventional gestational-age window. [4][21]
- Do not use tocolysis to pursue indefinite latency after steroid completion; the usual pharmacologic bridge is limited to approximately 48 hours. [5][14]
- When a patient has PPROM and an indication for delivery, corticosteroid eligibility does not convert a delivery indication into an indication for tocolysis. [14][20]

*Antenatal corticosteroid regimens and repeat-course trigger. [11]*

| Situation | Regimen | Timing rule |
| --- | --- | --- |
| Initial course | Betamethasone 12 mg IM every 24 hours for 2 doses. [11] | Use when preterm birth is anticipated. [11] |
| Initial course alternative | Dexamethasone 6 mg IM every 12 hours for 4 doses. [11] | Use when preterm birth is anticipated. [11] |
| Possible rescue course | Standard 48-hour regimen or a single betamethasone dose. [11] | Consider when the prior course was at least 7 to 14 days earlier and preterm birth risk has recurred. [11] |

## Use magnesium sulfate for imminent early preterm birth, not routine tocolysis

The indication is fetal neuroprotection when delivery is expected soon.

Administer antenatal magnesium sulfate when early preterm birth is imminent for fetal neuroprotection; it is distinct from magnesium used for seizure prophylaxis or treatment. Evidence supports a reduction in cerebral palsy risk with predelivery magnesium sulfate, whereas studies have not demonstrated effectiveness for prolonging pregnancy in preterm labor. [11][14]

A commonly recommended neuroprotection regimen is a 4-g intravenous loading dose over 20 to 30 minutes followed by 1 g/hour until birth or for 24 hours. A second cited regimen uses 6 g over 20 to 30 minutes followed by 2 g/hour until birth or for 12 hours, with protocolized restart rules; optimal dose, duration, timing, and repeat dosing remain uncertain. [10]

Before infusion, identify myasthenia gravis, neuromuscular disease, heart block, and renal dysfunction. Magnesium is renally cleared; use renal dosing in renal impairment and monitor vital signs, urine output, deep tendon reflexes, and cardiopulmonary examination for toxicity. [11] Avoid routine coadministration with calcium-channel blockers because of maternal respiratory-depression risk, except when magnesium is being given for neuroprotection and the clinical indication requires both therapies. [14]
- Do not substitute magnesium sulfate for a tocolytic chosen to achieve short-term pregnancy prolongation. [9][14]
- Do not extend magnesium exposure as maintenance therapy after the neuroprotection window solely to suppress contractions. [9][10]

*Magnesium sulfate selection and monitoring for fetal neuroprotection. [10][11][14]*

| Decision point | Action | Safety check |
| --- | --- | --- |
| Imminent early preterm birth | Use magnesium sulfate for fetal neuroprotection. [11][14] | Confirm delivery is sufficiently likely to justify treatment. [11] |
| Infusion regimen | 4 g IV over 20-30 minutes, then 1 g/hour until birth or 24 hours is a recommended regimen. [10] | Follow the institutional protocol for duration and any repeat dosing. [10] |
| Renal dysfunction or toxicity risk | Adjust dosing because magnesium is renally cleared. [11] | Assess urine output, reflexes, vital signs, and cardiopulmonary status. [11] |

## Reserve tocolysis for a defined short-term objective

Acute tocolysis is a bridge intervention, not a maintenance strategy.

When there is no contraindication to delaying birth, select acute tocolysis only to gain approximately 2 to 7 days for corticosteroid administration or transfer to a tertiary center; 48 hours is generally sufficient for the steroid and transport bridge. [5][14] The clinical objective should be recorded before treatment begins: complete corticosteroid dosing, complete transfer, or both.

Do not use maintenance tocolysis or repeated acute tocolysis as routine practice because neither improves perinatal outcome in the cited evidence summary. [5] Magnesium sulfate should not be selected as the uterine-relaxing agent for this purpose, because it has not demonstrated efficacy for pregnancy prolongation and high-dose or prolonged regimens have raised fetal safety concerns. [9][14]

Do not give antibiotics to prolong gestation in preterm labor with intact membranes; they do not appear to extend gestation. If preterm delivery is imminent, administer antibiotic prophylaxis for group B streptococci. [5] In PPROM, antibiotic and delivery decisions should follow a membrane-rupture pathway rather than the intact-membranes preterm labor pathway; guidelines agree on prophylactic antibiotics and corticosteroids from 24 to 34 weeks, but the optimal antibiotic regimen and several timing decisions vary across guidelines. [4]
- Stop the latency strategy and reassess for delivery if chorioamnionitis, maternal instability from bleeding, fetal deterioration, severe preeclampsia/eclampsia, or another delivery indication emerges. [14]
- Do not use a negative short-term delivery-risk test to override persistent maternal, fetal, or membrane-related indications for evaluation or delivery. [7][14]

*What to select—and avoid—for latency and antimicrobial management. [4][5][9][14]*

| Intervention | Appropriate role | Key limitation or exception |
| --- | --- | --- |
| Acute tocolysis | Short bridge for steroid exposure or maternal transfer when delaying delivery is safe. [5][14] | Avoid above 34 weeks and when a maternal, fetal, or infectious delivery indication is present. [14] |
| Maintenance or repeated acute tocolysis | No routine role. [5] | Does not improve perinatal outcome. [5] |
| Magnesium sulfate | Fetal neuroprotection with imminent early preterm birth. [11][14] | Not effective for pregnancy prolongation in preterm labor. [14] |
| Antibiotics with intact membranes | GBS prophylaxis when delivery is imminent. [5] | Do not use solely to prolong gestation. [5] |
| PPROM antibiotics | Use a PPROM-specific prophylactic antibiotic strategy. [4] | Optimal regimen varies among guidelines. [4] |

## References
1. International and national recommendations on risk screening and ... — www.thelancet.com — https://www.thelancet.com/pdfs/journals/lanogw/PIIS3050-5038(26)00120-2.pdf
2. Periviable birth: Interim update - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002937816300588
3. #3: Periviable birth - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002937815009059
4. Systematic review of national and international clinical practice ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S000293782500866X
5. Magnesium Sulfate - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/nursing-and-health-professions/magnesium-sulfate
6. Antenatal diagnosis of chorioamnionitis: A review of the potential ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/pd.6188
7. [PDF] Biomarker tests to help diagnose preterm labour in women ... - NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/htg476/documents/final-protocol
8. [PDF] national institute for health and care - NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/htg476/documents/final-scope
9. Different treatment regimens of magnesium sulphate for tocolysis in women in preterm labour — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8697562
10. Different magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birth - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11472847
11. Preterm Labor - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK536939
12. Antenatal Corticosteroids for Preterm Premature Rupture of Membranes: Single or Repeat Course? — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4460987
13. Magnesium sulphate for preventing preterm birth in threatened preterm labour - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10838393
14. Tocolysis - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK562212
15. Unit 8: Prelabor Rupture of Membranes and Intra-amniotic Infection — publications.aap.org — https://publications.aap.org/aapbooks/book/680/chapter/8190947/Prelabor-Rupture-of-Membranes-and-Intra-amniotic
16. Prevention of spontaneous preterm birth: Guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF) - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0301211516310971
17. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002937809004207
18. Nifedipine in the management of preterm labor: a systematic review and metaanalysis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002937810023185
19. Antenatal glucocorticoids, magnesium sulfate, and mode of birth in preterm fetal small for gestational age - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002937817327266
20. Management of cervical cerclage after preterm premature rupture of ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2589933324002957
21. What is the evidence? Updates in the use of antenatal corticosteroids for patients at risk of preterm birth — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2590161324000723
22. Outcomes of extremely preterm infants exposed to prolonged prelabor rupture of membranes before 24 weeks of gestation - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S000293782500016X
23. How can obstetricians improve outcomes for infants born extremely preterm? - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0146000521000914
24. Rescue doses of antenatal corticosteroids, children's ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2589933323000605

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.